Langerhans Cell Histiocytosis Clinical Trials

7 recruiting

Langerhans Cell Histiocytosis Trials at a Glance

15 actively recruiting trials for langerhans cell histiocytosis are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Minneapolis, Birmingham, and Chengdu. Lead sponsors running langerhans cell histiocytosis studies include West China Second University Hospital, Children's Hospital Medical Center, Cincinnati, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse langerhans cell histiocytosis trials by phase

Treatments under study

About Langerhans Cell Histiocytosis Clinical Trials

Looking for clinical trials for Langerhans Cell Histiocytosis? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Langerhans Cell Histiocytosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Langerhans Cell Histiocytosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis
National Cancer Institute (NCI)48 enrolled117 locationsNCT05828069
Recruiting
Phase 2

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Langerhans Cell Histiocytosis
Cook Children's Health Care System75 enrolled1 locationNCT06582745
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Not Applicable

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital120 enrolled11 locationsNCT07431060
Recruiting
Not Applicable

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital62 enrolled11 locationsNCT07371182
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 2

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

Langerhans Cell Histiocytosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT07187193
Recruiting
Phase 2

Mirdametinib in Histiocytic Disorders

Histiocytic DisordersRosai-Dorfman Disease (RDD)Langerhans Cell Histiocytosis (LCH)+1 more
Children's Hospital Medical Center, Cincinnati40 enrolled1 locationNCT06153173
Recruiting
Phase 3

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Langerhans Cell Histiocytosis
Baylor College of Medicine124 enrolled11 locationsNCT02670707
Recruiting
Phase 2

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital20 enrolled1 locationNCT07022834
Recruiting

Histiocytic Disorder Follow-up Study

HistiocytosisErdheim-Chester DiseaseRosai Dorfman Disease+3 more
University of Alabama at Birmingham6,000 enrolled1 locationNCT05915208
Recruiting
Phase 2Phase 3

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis
North American Consortium for Histiocytosis1,400 enrolled42 locationsNCT02205762
Recruiting
Phase 2

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Langerhans Cell HistiocytosisLCH
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.56 enrolled11 locationsNCT05997602
Recruiting
Phase 2

Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

Langerhans Cell Histiocytosis of Bone
Shanghai Changzheng Hospital118 enrolled1 locationNCT06078969
Recruiting
Phase 3

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

Langerhans Cell Histiocytosis
Shanghai Children's Medical Center200 enrolled1 locationNCT04773366